Red Mountain Compounding Pharmacy (First Royal Care Co. LLC), Mesa, AZ

Is Red Mountain Compounding Pharmacy (First Royal Care Co. LLC) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Red Mountain Compounding Pharmacy (First Royal Care Co. LLC) hold a Arizona pharmacy license?

State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.

Has Red Mountain Compounding Pharmacy (First Royal Care Co. LLC) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Sep 8, 2020), 1 warning letter close-out (Feb 13, 2023), 1 state referral letter (Feb 13, 2023) and 1 FMD-145 letter (Feb 13, 2023) for Red Mountain Compounding Pharmacy (First Royal Care Co. LLC). State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
First Royal Care Co. LLC; Red Mountain Compounding Pharmacy
Location
Mesa, AZ
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Feb 13, 2023
FDA Data Dashboard inspections
3 inspections: 2 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
3 Form 483s, 27 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as First Royal Care Co. LLC, (dba Red Mountain Compounding Pharmacy), a 503A facility, with 8 dated actions.

Document
Feb 13, 2023FMD-145 letterFMD-145 Letter Issued 02/13/2023Not linked by FDA
Feb 13, 2023Warning letter close-outWarning Letter Close Out (02/13/2023)FDA copy (archived)
Feb 13, 2023State referral letterState Referral Letter Issued 02/13/2023FDA copy (archived)
Sep 12, 2022Form 483483 Issued 09/12/2022FDA copy (archived)
Aug 11, 2021Form 483483 Issued 08/11/2021FDA copy (archived)
Sep 8, 2020Warning letterWarning Letter (09/08/2020)FDA copy (archived)
Dec 12, 2019Amended Form 483Amended 483 Issued 12/12/2019FDA copy (archived)
Jun 14, 2019Form 483483 Issued 06/14/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists First Royal Care Co. LLC, Mesa, AZ (FEI number 3015235235), matched to this page by exact name, city and state. It lists 3 inspections: 2 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 12, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30152352351179811
Aug 11, 2021Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30152352351149682
Jun 14, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30152352351092976

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 27 numbered observations in all, across 3 inspections ending Jun 14, 2019 to Sep 12, 2022. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 29, 2021 to Sep 12, 2022: 3 observations

Firm on the cover
First Royal Care Co. LLC, dba Red Mountain Compounding, 6828 E Brown Rd Ste 101, Mesa, AZ 85207-3761
FEI number
3015235235
Establishment type on the cover
Producer of Sterile and Non-Sterile Drugs
FDA district office on the cover
6th & Kipling St. (P.O. Box 25087) Denver CO 80225-0087
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

:

ISO-5 classified areas were not certified under dynamic conditions. Specifically, uni-directional airflow was not verified under operational conditions.

You never performed any dynamic smoke studies for your <Redacted B4> ISO Class 5 LAFW (laminar airflow workstation), model number <Redacted B4> serial number <Redacted B4>, which is used to produce all hazardous (hormonee) stterile drug products since approximately April 2022. In addition, on 09/01/22, your Lead Sterile Technician stated <Redacted B4> sealed the approximate <Redacted B4> inch circular opening on the back panel of the <Redacted B4> ISO Class 5 LAFW with <Redacted B4> when it was installed around April 2022. No studies have been performed to ensure the sealed opening does not leak or disrupt laminar airflow. Since approximately 05/31/22, your firm has produced and dispensed approximately <Redacted B4> lots of hazardous sterile drug products using this ISO Class 5 LAWF.

Observation 2

:

The ISO 5 classified equipment has difficult to clean surfaces.

Specifically, I observed <Redacted B4> back panel of your <Redacted B4> ISO Class 5 LAFW (laminar airflow workstation), model number <Redacted B4>, serial number <Redacted B4> , which is used to produce all hazardous (hormone) sterile drug products since approximately April 2022. On 09/01/22, your Lead Sterile Technician stated the <Redacted B4> is used to cover the mounting holes for <Redacted B4> lamps. ISO class 5 equipment surfaces should be completely smooth and easy to clean.

Add Continuation Page

Observation 3

:

Hazardous drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils and/or personnel to prevent cross-contamination.

Specifically, your written procedure titled Cleanroom Equipment Cleaning, SOP <Redacted B4>, version one, dated 03/18/22 does not include a deactivation agent when cleaning equipment and utensils used to produce hazardous sterile drug products. The equipment and utensils are non-dedicated and are used to produce both hazardous and non­hazardous sterile drug products. Since approximately 05/31/22, your firm has produced and dispensed approximately <Redacted B4> lots of sterile drug products which include approximately, <Redacted B4> lots of hazardous sterile drug products.

*Date(s) of Inspection: 08/29/22 (MON), 08/30/22 (TUE), 08/31/22 (WED), 09/01/22 (THU), 09/06/22 (TUE), 09/12/22 (MON)

Add Continuation Page

Inspection Jun 5, 2019 to Jun 14, 2019: 12 observations

Firm on the cover
First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy, 6828 E Brown Rd Ste 101, Mesa, AZ 85207-3761
FEI number
3015235235
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A) Your firm failed to validate equipment used to sterilize and depyrogenate equipment used in the production of sterile drng products.

B) Your firm does not verify <Redacted B4> 'through an endotoxin challenge. Therefore, there is no assurance that the <Redacted B4> for glassware used to prepare sterile injectable drug products achieves an appropriate reduction of endotoxin levels.

C) Equipment used in <Redacted B4> sterilization has never been qualified or calibrated.

D)[ (5) (4) studies have never been conducted to qualify the[(D) (4) I sterilization process; a biological incficatoris not used.

6 4 E) <Redacted B4> equipment and process used in the <Redacted B4> sterilization of product has not been qualified or procecturafrzed.

F) Media fills are conducted <Redacted B4> but do not include the most challenging process performed.

G) Dynamic smoke studies have been conducted but do not adequately demonstrate actual aseptic filling operations performed.

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

A) Sterile <Redacted B4> is used to disinfect gloves, but equipment and supplies introduced into the ISOS classified zone are wiped own with non-sterile wipes left open throughout the ISO classified zones. Sterile Prepackaged <Redacted B4> wipes are also used but for unspecified periods of time after breaking seal, rendering the wipes "non-sterile". Non-sterile <Redacted B4> based antiseptic hand wash was applied to steiile gloves dming production. (m

Specifically,

B) Disinfectants being used either do not provide sporicidal activity or have not been verified to provide sporicidal activity in the manner they are currently being used.

C) Container totes used to transfer supplies into the ISO7 classified buffer area are disinfected with non-sterile <Redacted B4> wipes.

D) Mixing bars used in sterile drug production are washed but not sterilized prior to use.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A) Environmental monitoring of ISO classified zones is conducted on a <Redacted B4> basis only.

B) Pressure differentials of classified areas are not monitored daily but on <Redacted B4> only.

D) Alarm systems to monitor for potential breaches in air quality are currently not employed.

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically, on 06/05/2019 and 6/7/2019 during the production of sterile product I observed the following:

The curtain used to demarcate the ISOS classified zone and control airflow was swaying therefore allowing dismptions in airflow. The curtain was observed to be too high to prevent the sterile drug tech from breaching the ISOS classified zone with exposed skin, while reaching for equipment.

Observation 5

Written records are not made of investigations into unexplained discrepancies.

Specifically,

On 02/04/2019 viable air samples exceeded bacterial and fungal limits in the ISO7 classified zones. No investigation was made to determine cause or some of contamination or to ensure patient safety was not compromised.

On 02/19/2019 viable air samples exceeded bacte1ial limits in the hazardous mug room. No investigation was made to dete1mine cause or somce of contamination or to ensme patient safety was not compromised.

Observation 6

Clothing of personnel engaged in the manufacturing and processing of drug products is not appropriate for the duties they perform.

Specifically, on 06/05/2019 and 06/07/2019 during production of sterile product I observed the following:

A) Non-Sterile clothing (head cover, mask, gown and booties) were used during production. Per the sterile drug tech and owner, this is the mandatory uniform employed during sterile drug production. The sterile tech was observed leaning against the bench and into the ISO5 classified zone repeatedly throughout production with exposed skin (neck, forehead and eyes).

B) During donning of production clothing, the sterile tech was observed allowing copious amounts of water to run from the elbows onto the floor of the anti-chamber. Booties were then donned on the wrong side of the demarcation line allowing for water to be tracked into the ISO7 classified buffer area.

Observation 7

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically,

Extended BUD's are established for high-risk products without the appropriate stability data or required sterility testing. For example:

1. S-Lidocaine HCL 1% MDV; BUD of 90 days.

2. S-Glutathione 200MG/ML MDV; BUD of 90 days.

3. S-Methylcobalamin 5000MCG/ML MDV INJ; BUD of 90 days.

Observation 8

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, sterility and pyrogen testing are not conducted on finished sterile drug products. For example:

1. Rx <Redacted B4> Lidocaine HCL 1 % MDV for Injection 1000ml, Lot S05012019DH@05.

5 2. Rx <Redacted B4> Glutathione 200MG/ML MDV for Injection 500ml, Lot S050820 l 9DH@07.

5 3. Rx <Redacted B4> Methylcobalamin S000MCG/ML MDV for Injection 600ml, Lot S04112019DT@08.

Observation 9

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the identity and strength of each active ingredient prior to release.

Specifically, potency testing is not conducted on finished drug products prior to release. For example:

5 1. Rx <R edacted B4> Lidocaine HCL 1 % MDV for Injection 1000ml, Lot S05012019DH@05.

5 2. Rx <Redacted B4> Glutathione 200MG/ML MDV for Injection 500ml, Lot S050820 l 9DH@07.

5 3. Rx <Redacted B4> Methylcobalamin S000MCG/ML MDV for Injection 600ml, Lot S04112019DT@08.

Observation 10

Written procedmes for cleaning and maintenance fail to include assignment of responsibility, description in sufficient detail of methods, equipment and materials used, description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance and instructions for protection of clean equipment from contamination prior to use.

of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance and instmctions for protection of clean equipment from contamination prior to use.

Specifically,

There were no cleaning SOP's to review which demonstrate actual procedures utilized at the facility. A generic, commercially available template SOP was provided but lacked any supporting information or detail that would reflect actual practices at your firm.

Cleaning practices observed on 06/07/2019 prior to sterile drug production are not reflected in SOP #: 3.020 "Cleaning and Maintenance of The Clean Room Facility". Multiple cleaning products utilized are not reflected in SOP #: 3.020 or lack procedural information such as frequency, location, dwell time and concentration. ...

Read the full 483 (PDF on fda.gov)

Observation 11

Batch production and control records for each batch of drug product produced do not include an accurate reproduction of the appropriate master production or control record which was checked for accuracy, dated and signed.

Specifically,

During sterile drug product review, the batch record for Rx <Redacted B4> Glutathione 200MG/ML MDV for Injection 500ml, Lot S050820 l 9DH@07, the API manufacturer in the formulation was incorrect but had been signed off as accurate by the Pharmacist. The conect API manufacturer was identified only because of the API still being on hand at that time.

Observation 12

Each batch of drug product required to be free of objectionable microorganisms is not tested through appropriate laboratory testing.

Specifically,

Non-sterile products are not tested for the presence of objectionable organisms at any time. For example:

1. Rx <Redacted B4> Kids Cocktail oral solution 480ml, Lot 03272019AT@25.

2. Rx <Redacted B4> Tretinoin 0.3% Topical Solution, Lot 05312019AT@29.

Inspection Jun 5, 2019 to Jun 14, 2019: 12 observations

Firm on the cover
First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy, 6828 E Brown Rd Ste 101, Mesa, AZ 85207- 3761
Establishment type on the cover
Producer of Sterile and Non-Sterile Drug Products
FDA district office on the cover
Irvine, CA 92612- 2445
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of diug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A) Your firm failed to validate equipment used to sterilize and depyrogenate equipment used in the production of sterile drng products.

B) Your fnm does not verify[(D) ("1-) I through an endotoxin challenge. Therefore, there is no assurance that the_~ -'l) for glassware used to prepare sterile injectable drng products achieves an appropriate reduction of endotoxm levels.

C) Equipment used in[(t5) ("1-) I sterilization has never been qualified or calibrated.

D)[(5) (4) studies have never been conducted to qualify the!(D) (4) I sterilization process; a biological indicator rs not used.

E)[@J_....,...(4_,)_ ...-_! equipment and process used in thetb)(4l sterilization of product has not been qualified or procecturahzed.

F) Media fills are conducted[(D) -(4) I but do not include the most challenging process performed.

G) Dynamic smoke studies have been conducted but do not adequately demonstrate actual aseptic filling operations performed.

AM ENDMENT2

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

(m

Specifically,

A) Ste1ile f(o) is used to disinfect gloves, but equipment and supplies introduced into the ISOS classified zone are wiped own with non-sterile wipes left open throughout the ISO classified zones. Sterile Prepackaged [(D) :(4) ] wipes are also used but for unspecified periods of time after breaking seal, rendering the wipes "non-

sterile". Non-ste1ileil5) (4 i -based antiseptic hand wash was applied to steiile gloves dming production.

B) Disinfectants being used either do not provide spo1icidal activity or have not been verified to provide spoiicidal activity in the manner they are cmTently being used. rfd Container totes used to transfer supplies into the ISO7 classified buffer area are disinfected with non-sterile ilb) (4 )l wipes.

D) Mixing bars used in sterile diug production are washed but not ste1ilized prior to use.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A) Environmental monito1ing of ISO classified zones is conducted on a ~ ) (-4 )j basis only. B) Pressure differentials of classified areas are not monitored daily but on 0 b) ( 4) I only.

AM ENDMENT2

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency paiiiculate air filters under positive pressme.

Specifically, on 06/05/2019 and 6/7/2019 dming the production of sterile product I observed the following:

The cmtain used to demarcate the 1SO5 classified zone and control airflow was swaying therefore allowing dismptions in airflow. The curtain was obse1ved to be too high to prevent the ste1ile dmg tech from breaching the 1SO5 classified zone with exposed skin, while reaching for equipment.

Observation 5

Written records ai·e not made of investigations into unexplained discrepancies.

Specifically, On 02/04/2019 viable air samples exceeded bacterial and fungal limits in the 1SO7 classified zones. No investigation was made to dete1mine cause or source of contamination or to ensure patient safety was not compromised. On 02/19/~ 2018 viable air samples exceeded bacterial limits in the hazardous diug room. No investigation was made to determine cause or source of contamination or to ensure patient safety was not compromised.

AMENDMENT2

Observation 6

Clothing of personnel engaged in the manufacturing and processing of dmg products is not appropriate for the duties they perform.

Specifically, on 06/05/2019 and 06/07/2019 dming production of ste1ile product I obse1ved the following:

A) Non-Sterile clothing (head cover, mask, gown and booties) were used during production. Per the ste1ile diug tech and owner, this is the mandato1y unifo1m employed during sterile diug production.

The ste1ile tech was obse1ved leaning against the bench and into the ISOS classified zone repeatedly throughout production with exposed skin (neck, forehead and eyes).

B) During donning of production clothing, the ste1ile tech was obse1ved allowing copious amounts of water to run from the elbows onto the floor of the anti-chamber. Booties were then donned on the wrong side of the demarcation line allowing for water to be tracked into the ISO7 classified buffer area.

Observation 7

There is no written testing program designed to assess the stability characteristics of diug products.

Specifically,

Extended BUD's are established for high-risk products without the approp1iate stability data or required ste1ility testing. For example:

1. S-Lidocaine HCL 1% MDV; BUD of90 days. 2. S-Glutathione 200MG/ML MDV; BUD of90 days. 3. S-Methylcobalamin S000MCG/ML MDV INJ; BUD of90 days.

AM ENDMENT2

Observation 8

Each batch of diug product pmpo1ting to be sterile and pyrogen-free is not laboratory tested to dete1mine confo1mance to such requirements.

Specifically, sterility and pyrogen testing are not conducted on finished ste1ile mug products. For example:

1. Rx l bHSY S-Lidocaine HCL 1 % MDV for Injection 1000ml, Lot S05012019DH@05. 2. Rx (b){G) S-Glutathione 200MG/ML MDV for Injection 500ml, Lot S05082019DH@07 S05082019DT@07. 3. Rx (b){G) S-Methykobalamin S000MCG/ML MDV for Injection 600ml, Lot S04112019DT@08.

Observation 9

Testing and release of di·ug product for distribution do not include appropriate laboratory dete1mination of satisfactory confo1mance to the identity and strength of each active ingredient prior to release.

Specifically, potency testing is not conducted on finished mug products prior to release. For example:

1. Rx'(b){sy S-Lidocaine HCL 1 % MDV for Injection 1000ml, Lot S05012019DH@05. 2. Rx (b){G) S-Glutathione 200MG/ML MDV for Injection 500ml, Lot S05082019DH@07 S05082019DT@07. 3. Rx (b){G) S-Methykobalamin S000MCG/ML MDV for Injection 600ml, Lot S04112019DT@08.

Observation 10

Written procedmes for cleaning and maintenance fail to include assignment of responsibility, description in sufficient detail of methods, equipment and materials used, description in sufficient detail

AM ENDMENT2

of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance and instmctions for protection of clean equipment from contamination prior to use.

Specifically,

There were no cleaning SOP's to review which demonstrate actual procedures utilized at the facility. A generic, commercially available template SOP was provided but lacked any suppo1ting info1mation or detail that would reflect actual practices at your fnm.

Cleaning practices obse1ved on 06/07/2019 prior to ste1ile dmg production are not reflected in SOP#: 3.020 "Cleaning and Maintenance of The Clean Room Facility". Multiple cleaning products utilized are not reflected in SOP #: 3.020 or lack procedural information such as frequency, location, dwell time and concentration. There are no procedures to review that reflects how equipment is broken down, cleaned or reassembled to prevent microbial contamination.

Observation 11

Batch production an d control records for each batch of diug product produced do not include an accurate reproduction of the appropriate master production or control record which was checked for accuracy, dated and signed.

Specifically, During ste1ile mug product review, the batch record for Rx'{b){GY S-Glutathione 200MG/ML MDV for Injection 500ml, Lot £05082019DH@07 S05082019DT@07, the API manufacturer in the fo1mulation was inconect but had been signed off as accurate by the Phrumacist. The conect API manufacturer was identified only because of the API still being on hand at that time.

AM ENDMENT2

Observation 12

Each batch of drng product required to be free of objectionable microorganisms is not tested through appropriate laborato1y testing.

Specifically,

Non-sterile products are not tested for the presence of objectionable organisms at any time. For example:

1. Rx'CbH5Y C-Kids Cocktail oral solution 480ml, Lot 03272019AT@25.

2. Rx'(b){sy C-Tretinoin 0.3% Topical Solution, Lot 05312019AT@29.

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Arizona are not checked: the board’s website, which hosts its license verification and board orders, answers automated requests with a bot challenge, and this index does not work around blocks.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.